Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology.
1
Division of Geriatrics, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15260, USA. Antonei@Csoka.us
Abstract
The term "Epigenetics" refers to DNA and chromatin modifications that persist from one cell division to the next, despite a lack of change in the underlying DNA sequence. The "epigenome" refers to the overall epigenetic state of a cell, and serves as an interface between the environment and the genome. The epigenome is dynamic and responsive to environmental signals not only during development, but also throughout life; and it is becoming increasingly apparent that chemicals can cause changes in gene expression that persist long after exposure has ceased. Here we present the hypothesis that commonly-used pharmaceutical drugs can cause such persistent epigenetic changes. Drugs may alter epigenetic homeostasis by direct or indirect mechanisms. Direct effects may be caused by drugs which affect chromatin architecture or DNA methylation. For example the antihypertensive hydralazine inhibits DNA methylation. An example of an indirectly acting drug is isotretinoin, which has transcription factor activity. A two-tier mechanism is postulated for indirect effects in which acute exposure to a drug influences signaling pathways that may lead to an alteration of transcription factor activity at gene promoters. This stimulation results in the altered expression of receptors, signaling molecules, and other proteins necessary to alter genetic regulatory circuits. With more chronic exposure, cells adapt by an unknown hypothetical process that results in more permanent modifications to DNA methylation and chromatin structure, leading to enduring alteration of a given epigenetic network. Therefore, any epigenetic side-effect caused by a drug may persist after the drug is discontinued. It is further proposed that some iatrogenic diseases such as tardive dyskinesia and drug-induced SLE are epigenetic in nature. If this hypothesis is correct the consequences for modern medicine are profound, since it would imply that our current understanding of pharmacology is an oversimplification. We propose that epigenetic side-effects of pharmaceuticals may be involved in the etiology of heart disease, cancer, neurological and cognitive disorders, obesity, diabetes, infertility, and sexual dysfunction. It is suggested that a systems biology approach employing microarray analyses of gene expression and methylation patterns can lead to a better understanding of long-term side-effects of drugs, and that in the future, epigenetic assays should be incorporated into the safety assessment of all pharmaceutical drugs. This new approach to pharmacology has been termed "phamacoepigenomics", the impact of which may be equal to or greater than that of pharmacogenetics. We provide here an overview of this potentially major new field in pharmacology and medicine.
- PMID:
- 19501473
- DOI:
- 10.1016/j.mehy.2008.10.039
- [Indexed for MEDLINE]
[105] Raap DK, Garcia F, Muma NA, Wolf WA, Battaglia G, van de Kar LD. Sustaineddesensitization of hypothalamic 5-Hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(Dipropylamino)Tetralin in the absence of changes in Gi/o/zproteins. J Pharmacol Exp Ther 1999;288:561–7.
[106] Faure C, Ouissame MF, Nasser H. Long-term adaptive changes induced by serotonergic antidepressant drugs. Expert Rev Neurother 2006;6:235–45.
[107] Palotas M, Palotas A, Puskas LG, Kitajka K, Pakaski M, Janka Z, et al. Gene expression profile analysis of the rat cortex following treatment with imipramine and citalopram. Int J Neuropsychopharmacol 2004;7:401–13.
[108] Kalman J, Palotas A, Juhasz A, Rimanoczy A, Hugyecz M, Kovacs Z, et al.Impact of venlafaxine on gene expression profile in lymphocytes of the elderly with major depression–evolution of antidepressants and the role ofthe ‘‘neuro-immune” system. Neurochem Res 2005;30:1429–38.
[109] Yamada M, Yamada M, Higuchi T. Antidepressant-elicited changes in gene expression: remodeling of neuronal circuits as a new hypothesis for drugefficacy. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:999–1009.
[110] Boehm C, Newrzella D, Herberger S, Schramm N, Eisenhardt G, Schenk V, et al. Effects of antidepressant treatment on gene expression profile in mousebrain: cell type-specific transcription profiling using laser microdissectionand microarray analysis. J Neurochem 2006;97(Suppl 1):44–9.
[111] Hyman SE. Even chromatin gets the blues. Nat Neurosci 2006;9:465–6.
[112] Newton SS, Duman RS. Chromatin remodeling: a novel mechanism of psychotropic drug action (relates to article by Cassel, et al. fastforward 2May 2006). Mol Pharmacol 2006;70:440–3.
[113] Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression andantidepressant action. Nat Neurosci 2006;9:519–25.
[114] Cassel S, Carouge D, Gensburger C, Anglard P, Burgun C, Dietrich JB, et al.
Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol Pharmacol 2006;70:487–92.
[115] Cohen AJ. Antidepressant-induced sexual dysfunction associated with low serum free testosterone. Psychiatry Online; 1999.
[116] Tanrikut C, Schlegel PN. Antidepressant-associated changes in semen parameters. Urology 2007;69:185.e5–7.
[117] Csoka AB, Shipko S. Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom 2006;75:187–8.
[118] Bolton JM, Sareen J, Reiss JP. Genital anaesthesia persisting six years after sertraline discontinuation. J Sex Marital Ther 2006;32:327–30.
[119] Kauffman RP, Murdock A. Prolonged post-treatment genital anesthesia and sexual dysfunction following discontinuation of citalopram and the atypicalantidepressant nefazodone. The Open Women’s Health J 2007;1:1–3.
[120] Csoka AB, Bahrick AS, Mehtonen O-P. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors (SSRIs). J Sex Med2008;5:227–33.
